PsoProtect is an international registry developed to enable clinicians to report outcomes of COVID-19 in individuals with psoriasis. It is hoped that PsoProtect will help us to understand how immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis and it will provide real-time updates on cases reported for the benefit of the dermatology community. PsoProtect seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.
IPC is pleased to be part of this important initiative and asks if you have a psoriasis patient diagnosed with COVID-19, please contribute to this important registry by submitting your case using the online PsoProtect case report form.
In addition, an adjoining registry PsoProtectMe has been set up for patients to self-report their experiences.
View the current data. You can also view our summary of the data collected from the first 50 cases, 200 cases, 1002 cases, 1118 cases.
WATCH NOW Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.
Latest news Dermavant Announces FDA Approval for VTAMA® (Tapinarof) CreamMay 26, 2022Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years. Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib DataMay 16, 2022Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis. Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 PandemicMay 11, 2022IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis. New Corporate MemberMay 03, 2022IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member! More News
